<div>
<p>Positron emission tomography (PET),
which uses positron-emitting radionuclides to visualize and measure processes
in the human body, is a useful noninvasive diagnostic tool for Alzheimer’s
disease (AD). The development of longer-lived radiolabeled compounds is
essential for further expanding the use of PET imaging in healthcare, and
diagnostic agents employing longer-lived radionuclides such as <sup>64</sup>Cu
(t<sub>1/2</sub> = 12.7 h, β<sup>+</sup> = 17%, β<sup>-</sup> = 39%, EC = 43%,
E<sub>max</sub> = 0.656 MeV) are capable of accomplishing this. One limitation
of <sup>64</sup>Cu PET agents is that they could release free radioactive Cu
ions from the metal complexes, which decreases the signal to noise ratio and
accuracy of imaging. Herein, a series of 1,4,7-triazacyclononane (TACN) and
2,11-diaza[3.3]-(2,6)pyridinophane (N4)-based <a>metal-chelating
compounds with pyridine arms were designed and synthesized by incorporating Aβ-interacting
fragments into metal-binding ligands, which allows for excellent Cu chelation
without diminishing their Aβ-binding affinity. </a>The crystal structures of the
corresponding Cu complexes confirmed the pyridine N atoms are involved in
binding to Cu. Radiolabeling and autoradiopraphy studies show that <a>the compounds efficiently chelate <sup>64</sup>Cu, and the
resulting complexes exhibit specific binding to the amyloid plaques in the AD mouse
brain sections vs. WT controls.</a></p>
</div>
<br>